Destiny Pharma - XF-73 enrolment paused by COVID-19
Destiny reported an operational loss of £5.58m for 2019 and ended the year with £7.48m in cash and equivalents, which it believes will provide a runway to Q421. We expect costs in 2020 to be lower than initial expectations due to the impact of COVID-19, which has caused the company to pause enrolment in its ongoing Phase IIb study of XF-73.Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.